TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events
Item 8.01
| Other Events. |
On May 30, 2017, Tonix Pharmaceuticals Holding Corp. (the
Company) presented an oral pipeline presentation entitled
Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for
the Treatment of Military-Related PTSD: Retrospective Analyses of
the Mediators and Moderators of Treatment Response (the
Presentation), at the 2017 American Society of Clinical
Psychopharmacology Annual Meeting, in Miami Beach, Florida (the
ASCP Meeting).
The foregoing description of the Presentation is qualified in its
entirety by reference to the Presentation, a copy of which is
filed as Exhibit99.01 to, and is incorporated by reference in,
this report.
On May 30, 2017, the Company issued a press release announcing
the Presentation at the ASCP Meeting. A copy of the press release
that discusses this matter is filed as Exhibit 99.02 to, and
incorporated by reference in, this report.
The information in this Current Report is being furnished and
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 |
Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response Presentation* |
| 99.02 |
Press Release, dated May 30, 2017, issued by Tonix Pharmaceuticals Holding Corp.* |
* Furnished herewith.
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session down -0.19 at 4.27 with 86,645 shares trading hands.